609 related articles for article (PubMed ID: 11440745)
21. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism.
Booij J; Speelman JD; Horstink MW; Wolters EC
Eur J Nucl Med; 2001 Mar; 28(3):266-72. PubMed ID: 11315592
[TBL] [Abstract][Full Text] [Related]
22. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
Parkinson Study Group
JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889
[TBL] [Abstract][Full Text] [Related]
23. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years.
Chouker M; Tatsch K; Linke R; Pogarell O; Hahn K; Schwarz J
Nucl Med Commun; 2001 Jun; 22(6):721-5. PubMed ID: 11403185
[TBL] [Abstract][Full Text] [Related]
24. [123I]beta-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients.
Müller T; Farahati J; Kuhn W; Eising EG; Przuntek H; Reiners C; Coenen HH
Eur Neurol; 1998; 39(1):44-8. PubMed ID: 9476723
[TBL] [Abstract][Full Text] [Related]
25. Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography.
Tatsch K; Schwarz J; Mozley PD; Linke R; Pogarell O; Oertel WH; Fieber RS; Hahn K; Kung HF
Eur J Nucl Med; 1997 Apr; 24(4):415-21. PubMed ID: 9096093
[TBL] [Abstract][Full Text] [Related]
26. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.
Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Sakamoto M
Ann Neurol; 1999 Nov; 46(5):723-31. PubMed ID: 10553989
[TBL] [Abstract][Full Text] [Related]
27. [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease.
Winogrodzka A; Bergmans P; Booij J; van Royen EA; Stoof JC; Wolters EC
J Neurol Neurosurg Psychiatry; 2003 Mar; 74(3):294-8. PubMed ID: 12588911
[TBL] [Abstract][Full Text] [Related]
28. Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis.
Schwarz J; Linke R; Kerner M; Mozley PD; Trenkwalder C; Gasser T; Tatsch K
Arch Neurol; 2000 Feb; 57(2):205-8. PubMed ID: 10681078
[TBL] [Abstract][Full Text] [Related]
29. SPECT-evaluation of the monoamine uptake site ligand [123I](1R)-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane ([123I]beta-CIT) in untreated patients with suspicion of Parkinson disease.
Eising EG; Müller TT; Zander C; Kuhn W; Farahati J; Reiners C; Coenen HH
J Investig Med; 1997 Oct; 45(8):448-52. PubMed ID: 9394097
[TBL] [Abstract][Full Text] [Related]
30. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
[TBL] [Abstract][Full Text] [Related]
31. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease.
Booij J; Tissingh G; Winogrodzka A; Boer GJ; Stoof JC; Wolters EC; van Royen EA
Eur J Nucl Med; 1997 Jan; 24(1):68-71. PubMed ID: 9044880
[TBL] [Abstract][Full Text] [Related]
32. Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.
Prunier C; Payoux P; Guilloteau D; Chalon S; Giraudeau B; Majorel C; Tafani M; Bezard E; Esquerré JP; Baulieu JL
J Nucl Med; 2003 May; 44(5):663-70. PubMed ID: 12732666
[TBL] [Abstract][Full Text] [Related]
33. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.
Ishikawa T; Dhawan V; Kazumata K; Chaly T; Mandel F; Neumeyer J; Margouleff C; Babchyck B; Zanzi I; Eidelberg D
J Nucl Med; 1996 Nov; 37(11):1760-5. PubMed ID: 8917170
[TBL] [Abstract][Full Text] [Related]
34. Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease.
Spiegel J; Hellwig D; Samnick S; Jost W; Möllers MO; Fassbender K; Kirsch CM; Dillmann U
J Neural Transm (Vienna); 2007 Mar; 114(3):331-5. PubMed ID: 16715205
[TBL] [Abstract][Full Text] [Related]
35. Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease.
Jeon B; Kim JM; Jeong JM; Kim KM; Chang YS; Lee DS; Lee MC
J Neurol Neurosurg Psychiatry; 1998 Jul; 65(1):60-4. PubMed ID: 9667562
[TBL] [Abstract][Full Text] [Related]
36. [[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy.
Berding G; Brücke T; Odin P; Brooks DJ; Kolbe H; Gielow P; Harke H; Knoop BO; Dengler R; Knapp WH
Nuklearmedizin; 2003 Feb; 42(1):31-8. PubMed ID: 12601452
[TBL] [Abstract][Full Text] [Related]
37. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.
Wenning GK; Donnemiller E; Granata R; Riccabona G; Poewe W
Mov Disord; 1998 May; 13(3):438-45. PubMed ID: 9613734
[TBL] [Abstract][Full Text] [Related]
38. Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease.
Scherfler C; Seppi K; Mair KJ; Donnemiller E; Virgolini I; Wenning GK; Poewe W
Brain; 2012 Nov; 135(Pt 11):3348-54. PubMed ID: 23043142
[TBL] [Abstract][Full Text] [Related]
39. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT.
Booij J; Hemelaar TG; Speelman JD; de Bruin K; Janssen AG; van Royen EA
J Nucl Med; 1999 May; 40(5):753-61. PubMed ID: 10319746
[TBL] [Abstract][Full Text] [Related]
40. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms.
Filippi L; Manni C; Pierantozzi M; Brusa L; Danieli R; Stanzione P; Schillaci O
Nucl Med Commun; 2005 May; 26(5):421-6. PubMed ID: 15838424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
